ArticleCell proliferation2008
Persistence of a chimerical phenotype after hepatocyte differentiation of human bone marrow mesenchymal stem cells.
Article in Cell proliferation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions.International journal of molecular sciences · 2021Review
- Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.Canadian journal of gastroenterology & hepatology · 2018Review
- Human bone marrow mesenchymal stem cell-derived hepatocytes improve the mouse liver after acute acetaminophen intoxication by preventing progress of injury.International journal of molecular sciences · 2014Article
- Hemophilia A: an ideal disease to correct in utero.Frontiers in pharmacology · 2014Review
- Inhibition of hepatic stellate cell proliferation by bone marrow mesenchymal stem cells via regulation of the cell cycle in rat.Experimental and therapeutic medicine · 2012Article
- Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene Delivery.Journal of genetic syndromes & gene therapy · 2012Article
- Mesenchymal stem cell-derived hepatocytes for functional liver replacement.Frontiers in immunology · 2012Article
- Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity.PloS one · 2012Article
- From hepatocytes to stem and progenitor cells for liver regenerative medicine: advances and clinical perspectives.Cell proliferation · 2011Article
- Emerging topics and new perspectives on HLA-G.Cellular and molecular life sciences : CMLS · 2011Review
- Cell proliferation of human bone marrow mesenchymal stem cells on biodegradable microcarriers enhances in vitro differentiation potential.Cell proliferation · 2010Article
- Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery.Advanced drug delivery reviews · 2010Review
- In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art.Stem cells (Dayton, Ohio) · 2009Review
- Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.World journal of gastroenterology · 2008Review
- Stem cells for liver tissue repair: current knowledge and perspectives.World journal of gastroenterology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecent studies have suggested the potential of mesenchymal stem cells (MSCs) to differentiate into a hepatocyte-like lineage. Here, we evaluate the efficacy of hepatocyte differentiation of MSCs by studying acquisition of hepatocyte-like features together with alteration of the native mesenchymal phenotype. MATERIAL AND
methodsIn vitro, we have investigated protein and mRNA level expression of hepatocyte and mesenchymal markers of mesenchymal-derived hepatocyte-like cells (MDHLCs) and we have evaluated their functionality using metabolic assays. In vivo, we investigated co-expression of hepatocyte (albumin, alpha-foetoprotein, cytokeratin 18) and mesenchymal (fibronectin, vimentin) markers after transplantation of MSCs or MDHLCs into severe combined immune deficiency mice.
resultsWe observed that while in vitro these cells acquired some phenotypic and functional features of mature hepatocytes, they partially preserved their mesenchymal phenotype. After intrasplenic transplantation, engrafted MSCs with isolated expression of fibronectin and alpha-foetoprotein were observed. When these cells were injected into the liver, they expressed all analysed markers, confirming the chimaeric co-expression observed in vitro. Conversely, liver-engrafted MDHLCs conserved their hepatocyte-lineage markers but lost their chimaeric phenotype.
conclusionsHepatocyte differentiation of MSCs predominantly allows the acquisition of phenotypic hallmarks and provides chimaeric cells that maintain expression of initial lineage markers. However, advanced maturation to the hepatocyte-like phenotype could be obtained in vivo by conditioning MSCs prior to transplantation or by infusing cells into the liver micro-environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.